Agent DCB

DEVICE2 trials

Sponsors

Boston Scientific Corporation, Medtronic Vascular

Conditions

Coronary Artery DiseaseIn-Stent Restenosis

Phase 3

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

Active, not recruitingNCT04647253

Boston Scientific CorporationIn-Stent Restenosis

Start: 2021-05-11End: 2027-09-01Updated: 2026-03-23

Unknown Phase

Prevail Global Study

RecruitingNCT06535854

Medtronic VascularCoronary Artery Disease

Start: 2025-02-24End: 2031-02-28Target: 1205Updated: 2025-10-24

Related Papers

Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.

2026-01-19

Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial.

2025-11-01

Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis

Journal of the American College of Cardiology2025-08-014 citations

Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease

American Heart Journal2025-01-233 citations

Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis

JAMA2024-03-09111 citations